Langbahn Team – Weltmeisterschaft

ICI-85966

ICI-85966
Clinical data
Other namesStilbostat; Diethylstilbestrol (DES) bis(di(2-chloroethyl)carbamate)
Identifiers
  • [4-[(E)-4-[4-[Bis(2-chloroethyl)carbamoyloxy]phenyl]hex-3-en-3-yl]phenyl] N,N-bis(2-chloroethyl)carbamate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H34Cl4N2O4
Molar mass604.39 g·mol−1
3D model (JSmol)
  • CC/C(=C(/CC)\C1=CC=C(C=C1)OC(=O)N(CCCl)CCCl)/C2=CC=C(C=C2)OC(=O)N(CCCl)CCCl
  • InChI=1S/C28H34Cl4N2O4/c1-3-25(21-5-9-23(10-6-21)37-27(35)33(17-13-29)18-14-30)26(4-2)22-7-11-24(12-8-22)38-28(36)34(19-15-31)20-16-32/h5-12H,3-4,13-20H2,1-2H3/b26-25+
  • Key:BOIZOYRDXIYMCY-OCEACIFDSA-N

ICI-85966 (former tentative brand name Stilbostat), also known as diethylstilbestrol (DES) bis(di(2-chloroethyl)carbamate), is a synthetic, nonsteroidal estrogen and cytostatic antineoplastic agent of the stilbestrol group and a nitrogen mustard ester of diethylstilbestrol (DES) which was developed for the treatment of breast cancer and prostate cancer but was never marketed (possibly due to the toxicity of DES).[1][2][3][4][5]

See also

References

  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 397. ISBN 978-1-4757-2085-3.
  2. ^ Zimel H, Broder D, Zimel A (1973). "[Therapeutic effects of the preparation "Stilbostat" in advanced stages of breast cancer after the menopause]". Stud Cercet Endocrinol (in Romanian). 24 (3): 211–9. PMID 4703920.
  3. ^ Görlich M, Heise E (1976). "Contribution to the mechanism of Stilbostat action". Neoplasma. 23 (4): 363–9. PMID 1004653.
  4. ^ Zimel H, Mogos I, Maltezeanu G (1977). "Estimation of StilbostatR treatment efficiency in breast cancer by thermography". Neoplasma. 24 (5): 553–7. PMID 927612.
  5. ^ Zimel H, Bocancea D (1974). "Treatment of prostatic carcinoma with Stilbostat". Neoplasma. 21 (1): 101–8. PMID 4596007.


Quelle: https://en.wikipedia.org/wiki/ICI-85966